These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 27668807)

  • 21. No off-target mutations in functional genome regions of a CRISPR/Cas9-generated monkey model of muscular dystrophy.
    Wang S; Ren S; Bai R; Xiao P; Zhou Q; Zhou Y; Zhou Z; Niu Y; Ji W; Chen Y
    J Biol Chem; 2018 Jul; 293(30):11654-11658. PubMed ID: 29941452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
    Chemello F; Olson EN; Bassel-Duby R
    Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.
    Chen G; Wei T; Yang H; Li G; Li H
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating Genetic Disorders Using State-Of-The-Art Technology.
    Jamal M; Ullah A; Ahsan M; Tyagi R; Habib Z; Khan FA; Rehman K
    Curr Issues Mol Biol; 2018; 26():33-46. PubMed ID: 28879854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies.
    Chey YCJ; Arudkumar J; Aartsma-Rus A; Adikusuma F; Thomas PQ
    WIREs Mech Dis; 2023 Jan; 15(1):e1580. PubMed ID: 35909075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review.
    Babačić H; Mehta A; Merkel O; Schoser B
    PLoS One; 2019; 14(2):e0212198. PubMed ID: 30794581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo genome editing improves motor function and extends survival in a mouse model of ALS.
    Gaj T; Ojala DS; Ekman FK; Byrne LC; Limsirichai P; Schaffer DV
    Sci Adv; 2017 Dec; 3(12):eaar3952. PubMed ID: 29279867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.
    Nelson CE; Hakim CH; Ousterout DG; Thakore PI; Moreb EA; Castellanos Rivera RM; Madhavan S; Pan X; Ran FA; Yan WX; Asokan A; Zhang F; Duan D; Gersbach CA
    Science; 2016 Jan; 351(6271):403-7. PubMed ID: 26721684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
    Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
    Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR for Neuromuscular Disorders: Gene Editing and Beyond.
    Young CS; Pyle AD; Spencer MJ
    Physiology (Bethesda); 2019 Sep; 34(5):341-353. PubMed ID: 31389773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.
    Tremblay JP; Iyombe-Engembe JP; Duchêne B; Ouellet DL
    Mol Ther; 2016 Nov; 24(11):1888-1889. PubMed ID: 27916992
    [No Abstract]   [Full Text] [Related]  

  • 32. Toward In Vivo Gene Therapy Using CRISPR.
    Skipper KA; Mikkelsen JG
    Methods Mol Biol; 2019; 1961():293-306. PubMed ID: 30912053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.
    Vita G; Vita GL; Musumeci O; Rodolico C; Messina S
    Neurol Sci; 2019 Apr; 40(4):671-681. PubMed ID: 30805745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The progress of AAV-mediated gene therapy in neuromuscular disorders.
    Aguti S; Malerba A; Zhou H
    Expert Opin Biol Ther; 2018 Jun; 18(6):681-693. PubMed ID: 29781327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In dogs, CRISPR fixes a muscular dystrophy.
    Cohen J
    Science; 2018 Aug; 361(6405):835. PubMed ID: 30166469
    [No Abstract]   [Full Text] [Related]  

  • 36. Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy.
    Wasala NB; Hakim CH; Chen SJ; Yang NN; Duan D
    Hum Gene Ther; 2019 May; 30(5):535-543. PubMed ID: 30648435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy.
    Wang DN; Wang ZQ; Jin M; Lin MT; Wang N
    Gene Ther; 2022 Dec; 29(12):730-737. PubMed ID: 35534612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.
    Sharma G; Sharma AR; Bhattacharya M; Lee SS; Chakraborty C
    Mol Ther; 2021 Feb; 29(2):571-586. PubMed ID: 33238136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scalpel or Straitjacket: CRISPR/Cas9 Approaches for Muscular Dystrophies.
    Himeda CL; Jones TI; Jones PL
    Trends Pharmacol Sci; 2016 Apr; 37(4):249-251. PubMed ID: 26917062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.